Today, we're digging into a topic that's getting a lot more attention lately, how early decisions in cell therapy end up shaping or complicating everything that comes later. Our episode today is Freeze Variability, Not Progress, How to Strengthen Your Cell Therapy Supply Chain from the Start, and we're going to challenge a few long-held beliefs about how starting material should be handled.
My guest today is Dominic Clarke, Vice President of Technical Operations for IntegriCell at Cryoport Systems. Dominic has spent years in the trenches building and scaling cell therapy processes from early development through commercialization. So, he's seen where things break and what actually works. I hope you enjoy my conversation with Dominic Clark.
01:07 Meet Dominic Clarke and Cryoport Systems
06:24 Fresh cells versus frozen cells
08:21 Why teams switch to cryopreservation late
12:37 The challenge of variability
16:47 IntegriCell when you already have a process in place
22:17 An argument for cryopreservation based on data
25:56 The future of IntegriCell and Cryoport Systems
This episode is brought to you with the support of Cryoport Systems.
Podden och tillhörande omslagsbild på den här sidan tillhör
Labiotech. Innehållet i podden är skapat av Labiotech och inte av,
eller tillsammans med, Poddtoppen.
